Meeting Expectations: US FDA Communications Getting High Marks – Before COVID, At Least
Executive Summary
FDA’s interactions with sponsors to support drug development activities are generally timely and effective – but industry still sees room for improvement in assuring ‘best practices’ are followed across all divisions.
You may also be interested in...
A More Perfect Meeting: Industry Seeks Additional PDUFA VII Metrics To Improve Communications
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?
US FDA Urged To Drop Snail Mail For IND Communications
Waiting for paper letters to arrive can delay drug development, companies contend, but moving completely to e-communication may be difficult for the FDA.
US FDA Picks Up The Pace Of Complete Response Letters Over June And July
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.